IAM217 / Iambic Therap - LARVOL DELTA

A novel KIF18A inhibitor for targeting chromosomal instability in cancer (AACR 2025) - "IAM-K1 has robust anti-proliferation activity in a number of cell lines, representing different cancer indications, and is approximately 2-3 fold more potent than a reference compound AMG650. The anti-tumor activity is correlated with an increase in pHH3 in xenograft tumors, consistent with the on-target mechanism of mitotic arrest. Together with a predictive biomarker approach, targeting KIF18A with IAM-K1 and other compounds in this series is expected to provide a novel anti-cancer treatment to patients with a wide therapeutic window."

Oncology • KIF18A

Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference (Businesswire) - "Dr. Miller will detail progress and anticipated milestones for Iambic’s emerging pipeline of development candidates, as well as advances to its AI drug discovery platform. The Company’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs."

Clinical • Oncology • Solid Tumor